NIDA Funding Strategy for Fiscal Year 2009 | NIDA Archives

National Institutes of Health

This is Archived Content. This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA). View current information on nida.nih.gov.

Based on the enacted Omnibus appropriation, the National Institute on Drug Abuse (NIDA) has established the following funding policy.

New and Competing (Type 1 & 2)

New and competing grants will be funded at a 3% increase over FY 2008.

Non-competing Continuations (Type 5)

All non-competing continuations (modular and non-modular) will be funded at 100% of committed levels.
Information regarding the NIH NIH Fiscal Policy for Grant Awards - FY 2009 can be found at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-066.html

New Investigators

NIDA is committed to supporting first-time R01 investigators and Early Stage Investigators (by NIH definition). This means new investigator status will be considered in funding decisions and is one factor in funding grants beyond the normal payline. For the policy on New and Early Stage Investigators go to http://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-013.html.

Ruth L. Kirschstein National Research Service Awards (NRSA)

NIH has established new increased stipend levels for fiscal year 2009 NRSA awards. For more information visit http://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-075.html